Clinical Trials Logo
  1. Home
  2. Oligometastasis
  3. NCT04677192

Microwave Ablation Combined With Chemotherapy in the Treatment of Pancreatic Cancer Oligohepatic Metastasis

Oligometastasis Clinical Trial

Official title:
Effectiveness and Safety Evaluation of Microwave Ablation Combined With Chemotherapy in the Treatment of Pancreatic Cancer Oligohepatic Metastasis: A Prospective, Single-center, Single-arm, Phase II Clinical Study

Clinical Trial Summary

This study is a prospective, single center, single arm, phase II clinical study in patients with liver metastasis after radical resection of pancreatic cancer. The purpose of this study is to evaluate the clinical value of microwave ablation combined with chemotherapy for liver metastasis after radical resection of pancreatic cancer about overall survival, and to determine the feasibility and safety of the scheme.

Clinical Trial Description

Microwave ablation, as one of the important treatment methods of liver metastases, has the advantages of radical effect, small trauma and rapid recovery.Microwave ablation combined with chemotherapy aims to improve the quality of life and prolong the survival time.The purpose of this study is to evaluate the clinical value of microwave ablation combined with chemotherapy for liver metastasis after radical resection of pancreatic cancer about overall survival, and to determine the feasibility and safety of the scheme. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04677192
Study type Interventional
Source Fudan University
Contact Yongqiang Hua, Deputy chief physician
Phone (021)64175590
Email keqiang1215@126.com
Status Not yet recruiting
Phase Phase 2
Start date January 2021
Completion date December 2022
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03796767 - Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer Phase 2
Recruiting NCT04085029 - Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
Not yet recruiting NCT04486287 - Sintilimab After Stereotactic Ablation Brachytherapy for Refractory Oligometastatic Non-Small Cell Lung Cancer Phase 2
Recruiting NCT06135714 - Metastasis-directed Therapy for Oligometastases of Breast Cancer Phase 3
Recruiting NCT03965468 - Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC Phase 2
Recruiting NCT04158843 - Radical Local vs. Palliative Therapy for Breast Cancer Patientts With Ipsilateral Humerus or Sternum Oligometastasis N/A
Recruiting NCT04172753 - Feasibility of Online MR-guided Radiotherapy on a 1.5T MR-Linac N/A
Recruiting NCT04498767 - Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE) N/A
Recruiting NCT04787744 - Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer Phase 2/Phase 3
Recruiting NCT04221516 - Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma Phase 2
Recruiting NCT03161522 - Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer Phase 2
Recruiting NCT04641078 - Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer Phase 2
Active, not recruiting NCT03630666 - Comparison of Intermittent Androgen Deprivation Therapy With or Without Irradiation Recovery in Prostate Cancer Patients N/A
Recruiting NCT05055583 - Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC Phase 2
Recruiting NCT05352178 - Metastasis-directed Therapy for Oligorecurrent Prostate Cancer Phase 3